Results 151 to 160 of about 573,436 (265)
Features of Thyroid Lymphoma: A Single-Center Experience. [PDF]
Battistella E +6 more
europepmc +1 more source
Clock Genes Regulate Ca2+ Signaling and Mitochondrial Bioenergetics to Inhibit Sjögren Disease
Objective Although Ca2+ signaling and metabolism have been identified as key determinants for the development of Sjögren disease (SjD), the intricate connection between them and salivary gland physiology remains poorly understood. Methods Fluorescence‐based Ca2+ imaging, RNA sequencing, and mitochondrial activity were used to investigate the effects of
Viktor R. Drel +12 more
wiley +1 more source
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Reversal of Cerebral Glucose Hypometabolism in a Patient with COVID and Refractory B-Cell Lymphoma. [PDF]
Decosma L, Wolf E, Parent EE, Tun HW.
europepmc +1 more source
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T‐cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova +6 more
wiley +1 more source
Extranodal marginal zone lymphoma presenting as a paraspinal mass and pleural effusion. [PDF]
Cami B +5 more
europepmc +1 more source
[Malignant lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma)].
openaire +2 more sources
Distinct molecular pathways supporting Sjögren's Disease clusters and disease progression.
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined SjD patient clusters: (1) B‐cell active with low symptoms (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptoms (LSAHS).
Sacha E Silva‐Saffar +6 more
wiley +1 more source

